UK’s NICE Says Alzheimer’s Disease Drug Kisunla Is Not Cost-Effective

The Alzheimer's disease drug Kisunla will face major reimbursement challenges in the U.K. after the cost-effectiveness watchdog, NICE, said the drug isn't cost-effective.